Rezultati - Hannah E. Pearson
- Showing 1 - 3 results of 3
-
1
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy od Mari Iida, Toni M. Brand, Megan M. Starr, Evan J Huppert, Neha Luthar, Harsh Bahrar, John P. Coan, Hannah E. Pearson, Ravi Salgia, Deric L. Wheeler
Izdano 2014Artigo -
2
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma od Toni M. Brand, Mari Iida, Andrew P. Stein, Kelsey L. Corrigan, Cara M. Braverman, John P. Coan, Hannah E. Pearson, Harsh Bahrar, Tyler L. Fowler, Bryan Bednarz, Sandeep Saha, David T. Yang, Parkash S. Gill, Mark W. Lingen, Vassiliki Saloura, Victoria Villaflor, Ravi Salgia, Randall J. Kimple, Deric L. Wheeler
Izdano 2015Artigo -
3
MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents od Nellie K. McDaniel, Christopher T. Cummings, Mari Iida, Justus Hülse, Hannah E. Pearson, Eleana Vasileiadi, Rebecca E. Parker, Rachel A. Orbuch, Olivia J. Ondracek, Noah B. Welke, Grace H. Kang, Kurtis D. Davies, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Paul M. Harari, Randall J. Kimple, Deborah DeRyckere, Douglas K. Graham, Deric L. Wheeler
Izdano 2018Artigo
Iskalna orodja:
Sorodne teme
Cancer research
Antibody
Cetuximab
Head and neck cancer
Head and neck squamous-cell carcinoma
Immunology
Internal medicine
Medicine
Monoclonal antibody
Receptor
AXL receptor tyrosine kinase
Antibody-dependent cell-mediated cytotoxicity
Basal cell
Biology
Cancer
Cell biology
Cell culture
Chemotherapy
ERBB3
Epidermal growth factor receptor
GAS6
Gene knockdown
Genetics
Head and neck
JAK-STAT signaling pathway
MERTK
Malignancy
Neuregulin 1
Oncology
PI3K/AKT/mTOR pathway